JAK-STAT Signalling: Cytokine Receptors, JAKs, STATs and Assays

Dozens of cytokines converge on four kinases and seven transcription factors. That compression is the problem JAK–STAT has to solve, and it is why this map is drawn as receptor, kinase and STAT columns rather than a linear cascade. Specificity is not built into the kinases — JAK1 serves the interferons, IL-6 and IL-2 alike. It is built into which receptor tail a STAT can dock on, which promoter element the resulting dimer reads, and which brake closes that arm first.

Four receptor families feeding one signalling module

The map is organised by receptor family because that is where the biology diverges. Type II interferon runs through IFNGR1 and IFNGR2; type I through IFNAR1 and IFNAR2, which read IFN-β and the IFN-α subtypes. The common γ-chain group pairs IL2RG (γc) with IL2RB for IL-2 and with IL4R for IL-4. IL-6 uses IL6R with gp130, and IL-12 uses IL12RB1 with IL12RB2. None of these chains has enzymatic activity.

Two features repay attention. The chains are not equivalent: IFNAR2 carries the high-affinity site while IFNAR1 discriminates IFN-β from the α subtypes, so a cell can be responsive on one chain and refractory on the other. Several chains are also shared — IL2RB and IL2RG serve IL-15, IL12RB1 serves IL-23 — which is why receptor readouts move when you have not touched the cytokine you were studying.

The Janus kinases and the pairing rules

Each Janus kinase is held on the receptor tail by its FERM–SH2 module and sits idle until ligand brings two chains close enough to trans-phosphorylate. The name is literal: JAKs carry two kinase-like domains, an active JH1 and a catalytically dead pseudokinase JH2 that clamps JH1 off. That clamp is the most consequential structure here. The JAK2 V617F mutation of myeloproliferative neoplasms sits in JH2 and never touches the catalytic site — it simply releases the brake.

The pairing rules are fixed and predict every deficiency phenotype on the map. JAK3 associates exclusively with γc, partnered by JAK1 on the other chain. IFNGR1 carries JAK1 and IFNGR2 carries JAK2. IFNAR2 carries JAK1 and IFNAR1 carries TYK2. gp130 can recruit JAK1, JAK2 and TYK2 but depends functionally on JAK1. IL12RB1 uses TYK2, IL12RB2 uses JAK2.

STAT selection: docking sites, dimers and promoter elements

Once the JAKs fire they phosphorylate tyrosines on the receptor's own tail, and those motifs — not any preference of the kinase — decide which STAT is recruited. A STAT SH2 domain reads a specific phosphotyrosine context, is phosphorylated on one conserved C-terminal tyrosine (STAT1 Y701, STAT3 Y705, STAT5 Y694), then swaps into a reciprocal dimer. Exchange those motifs between two receptor tails and the STAT output exchanges with them: the receptor, not the kinase, is the specificity element.

The dimers then read different DNA. STAT1 homodimers bind GAS elements downstream of IFN-γ, while type I interferon builds ISGF3 — STAT1, STAT2 and IRF9 — which binds ISREs instead. STAT4 carries IL-12 into Th1, STAT6 carries IL-4 into Th2, STAT3 carries IL-6 into Th17, STAT5 carries IL-2 into FOXP3. The non-obvious part: STAT3 and STAT5 compete for overlapping sites at the Il17 and Foxp3 loci, so IL-2 restrains Th17 simply by occupying the DNA first.

The brakes: SOCS, CIS, PIAS and the phosphatases

With nothing between receptor and nucleus, the pathway has almost no intrinsic decay — duration is set by inhibitors, and all of them are STAT target genes. SOCS1 carries a kinase inhibitory region acting as a pseudosubstrate inside the JAK active site, plus a SOCS box that recruits an elongin–cullin E3 ligase to degrade the complex. SOCS3 works identically but must dock on gp130 Y757 first, which makes it selective for the IL-6 family. CIS is STAT5-induced and closes down IL-2.

The other classes act after phosphorylation. PIAS1 blocks STAT1 from binding DNA and PIAS3 does the same to STAT3, sterically rather than catalytically, so phospho-STAT can look normal on a blot while transcription has already stopped. SHP-2 (PTPN11) is bidirectional: it dephosphorylates JAKs and STATs but also couples gp130 to RAS–ERK. TC-PTP (PTPN2) acts in the nucleus on STAT1 Y701 and STAT3 Y705, and its deletion is a recurring tumour CRISPR-screen hit because it leaves an exaggerated IFN-γ response.

Where the pathway breaks, and where it is drugged

Human genetics maps onto these columns almost node for node. Loss of JAK3 or IL2RG gives SCID. Loss of IFNGR1 or IFNGR2 gives Mendelian susceptibility to mycobacterial disease with otherwise unremarkable immunity, while TYK2 deficiency adds viral susceptibility because it serves both the IL-12 and type I interferon arms. Gain-of-function STAT1 causes chronic mucocutaneous candidiasis by suppressing Th17 output; dominant-negative STAT3 causes hyper-IgE syndrome.

The same convergence makes the pathway druggable and limits it. Tofacitinib targets JAK1/JAK3, ruxolitinib JAK1/JAK2, upadacitinib leans JAK1-selective, and deucravacitinib is the outlier: it binds the TYK2 JH2 pseudokinase domain rather than the conserved ATP pocket, achieving selectivity that active-site chemistry cannot. The practical point is that JAK selectivity means little in isolation. What matters is which receptor context loses signal, so read STAT1, STAT3, STAT5 and STAT6 in parallel.

Key targets and matching reagents

Studying JAK–STAT signalling in vivo

Everything from the JAKs inward is intracellular, so in vivo intervention happens at the ligand and occasionally at the receptor. Experiments fall into three groups.

1. Neutralising the cytokine input

Functional-grade anti-mouse IFN-γ (XMG1.2), anti-mouse IFN-β, anti-mouse IL-2 (JES6-1A12) and anti-mouse IL-4 (11B11) remove one input at a time and show which STAT column a phenotype was riding on. Because the receptors converge, this is cleaner than inhibitor work: blocking IFN-γ while leaving type I interferon intact separates the GAS output from the ISRE output in a way no JAK compound can. Use low-endotoxin, azide-free material — residual LPS induces type I interferon and IL-6 directly.

2. Resolving which kinase and which STAT carries the signal

Run the module as a panel. JAK1, JAK2, JAK3 and TYK2 establish which kinases the tissue expresses; STAT1, STAT2, STAT3, STAT4, STAT5 and STAT6 show where the output went. Add IRF9 whenever type I interferon is in play — ISGF3 cannot form without it, so an ISG-poor sample with normal STAT1 and STAT2 usually means IRF9 is limiting rather than the receptor.

3. Quantifying the receptors and the brakes

Unexplained phenotypes usually sit in the regulatory column. Assay SOCS1, SOCS3 and CIS for feedback capacity, PIAS1 and PIAS3 for the DNA-binding block that leaves phospho-STAT intact, and SHP-2 with PTPN2 for the phosphatase arm. On the receptor side, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IL2RB, IL2RG, IL4R, IL6R, gp130, IL12RB1 and IL12RB2 separate absent ligand from absent chain. Pair with IL-6 and IL-12 ELISAs on the input side.

Featured products for this pathway

Frequently asked questions

For research use only. Not for use in diagnostic or therapeutic procedures.